The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
July 20, 2021
Canexia Health recently sponsored a virtual roundtable, hosted by GenomeWeb, focused on disparities in access to precision oncology. Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health discussed their perspectives working within small and large health systems across the US.
July 13, 2021
Liquid biopsy has become a useful tool for targeted cancer treatment selection.
June 22, 2021
Last year, by Precision Oncology News’ count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.
May 4, 2021
Microsatellites are short, repeating DNA segments that can play a major role in studying cancers.
April 20, 2021
Precision medicine instruments produce incredible amounts of data, sometimes measured in terabytes or even petabytes.
March 11, 2021
If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.
March 2, 2021
Canexia Health's Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.
February 17, 2021
Here are three examples of value-based care initiatives that are also focused on reducing disparities and inequity in cancer care.
February 4, 2021
This article from The Globe and Mail covers Project ACTT, a federally funded project, led by Canexia Health, which offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.